Insulet (PODD) Misses Q4 EPS by 22c, Guidance Comes in Light

Insulet (NASDAQ: PODD) reported Q4 EPS of ($0.48), $0.22 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $100.1 million versus the consensus estimate of $91.89 million.

GUIDANCE:

Insulet sees Q1 2016 revenue of $77-80 million, versus the consensus of $83.19 million.

Insulet sees FY2016 revenue of $330-350 million, versus the consensus of $360.08 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c